Anemia is one of the most common complications among patients with chronic kidney disease (CKD), significantly impacting their quality of life. As the CKD worsens prevalence of anemia increases in patients. The current standard of care in Anemia of CKD is IV/ Oral Iron and Erythropoietin analogues. Novel treatment Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) - Desidustat endogenously stimulates the Erythropoietin production. Hence, this retrospective analysis is planned to look in to real world outcome of Desidustat in CKD – Anemia.
No takes yet. Share an insight, caveat, or question.
Hiremath et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: